8-K Announcements
6Material company update
Jan 23, 2026·SEC
Material company update
Jan 21, 2026·SEC
Material company update
Dec 23, 2025·SEC
Astria Therapeutics, Inc.(ATXS)Earnings, Financials & Key Ratios
ATXS•NASDAQ
$12.58
Price updated Jun 20, 2026
AboutAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.Show more
- Revenue$0
- EBITDA-$112M-13.6%
- Net Income-$94M-29.3%
- EPS (Diluted)-1.68+30.6%
- ROE-33.52%-6.8%
ATXS Price & Volume
Astria Therapeutics, Inc. (ATXS) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Revenue Generation Potential
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Single-asset clinical dependency
Key Thesis Takeaways
- Astria Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on the clinical success of its lead candidate, STAR-0215.
- While the company maintains a current ratio of 10.78, the consistent quarterly operating losses, which reached $34.1 million in 2025Q3, suggest a precarious path toward commercialization.
- Investors should monitor the company's ability to manage its $96.3 million cash position against the intensive R&D requirements that have historically driven significant equity dilution.
Verdict Logic
the company's reliance on external financing is underscored by a cash position that has declined to $96.3 million, creating substantial risk for shareholders as the firm continues to burn over $30 million per quarter.
ATXS Growth Metrics
Astria Therapeutics, Inc. (ATXS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-2.38%
Return on Capital
10 Years-92.64%
5 Years-88.23%
3 Years-35.42%
Last Year-39.4%
ATXS Recent Earnings
Astria Therapeutics, Inc. (ATXS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 0/12 qtrs (0%)
Q4 2025Latest
Nov 12, 2025Metric
Actual
Est
EPS
$0.55-34.1%
$0.41
Rev
$706,000-93.4%
$11M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.57+6.6%
$0.61
Rev
—
$11M
Q2 2025
May 13, 2025Metric
Actual
Est
EPS
$0.58-20.8%
$0.48
Rev
—
—
Q2 2025
Mar 11, 2025Metric
Actual
Est
EPS
$0.44+2.2%
$0.45
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 12, 2025 | $0.55vs $0.41-34.1% | $706,000vs $11M-93.4% |
| Q3 2025 | Aug 12, 2025 | $0.57vs $0.61+6.6% | —vs $11M |
| Q2 2025 | May 13, 2025 | $0.58vs $0.48-20.8% | — |
| Q2 2025 | Mar 11, 2025 | $0.44vs $0.45+2.2% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Astria Therapeutics, Inc. (ATXS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $12.58 | $718.13M | -7.49 | — | — | -33.52% | — | |
| $27.00 | $1.44B | -8.36 | — | -119.44% | -1057.44% | — | |
| $4.08 | $5.15M | -0.08 | -81.82% | -2530.85% | — | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — | |
| $5.38 | $1.32B | -20.69 | 22.09% | -13.58% | -38.11% | — |
Compare ATXS vs Peers
Astria Therapeutics, Inc. (ATXS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATXS SEC Filings & Documents
Astria Therapeutics, Inc. (ATXS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ATXS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATXS Frequently Asked Questions
Astria Therapeutics, Inc. (ATXS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Astria Therapeutics, Inc.'s revenue?
Astria Therapeutics, Inc. (ATXS) reported $0.7M in revenue for fiscal year 2024.
Is ATXS profitable?
Astria Therapeutics, Inc. (ATXS) reported a net loss of $124.0M for fiscal year 2024.
Dividend & Returns
What is ATXS's return on equity?
Astria Therapeutics, Inc. (ATXS) has a return on equity (ROE) of -33.5%. Negative ROE indicates the company is unprofitable.
What is Astria Therapeutics, Inc.'s free cash flow?
Astria Therapeutics, Inc. (ATXS) had negative free cash flow of $120.3M in fiscal year 2024, likely due to heavy capital investments.